QUOTIENT

Topic of Study: Inflammatory Bowel Disease

Sponsor: University of California, San Diego

Principal Investigator: Raymond K. Cross Jr., M.D., M.S., 410-332-9356

Research Coordinator: Makena Trout, 410-659-2829; Liyah Courageux, 410-332-9356

Coordinated Through: Institute for Digestive Health and Liver Diseases

This is a pragmatic, open-label, multicenter randomized controlled trial conducted in asymptomatic patients with IBD who have persistent moderate to severe endoscopic inflammation despite optimization of index targeted immunomodulatory (TIM). This clinical trial aims to collect and analyze data in patients with IBD who are currently receiving IBD medication(s) that targets their immune system (TIM) in routine clinical care, and to determine if switching to an alternative IBD medications will improve their disease outcome without increasing the burden of their treatment. (Clinicaltrials.gov ID# NCT05230173)